{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T17:27:49.140540+00:00","company":{"ticker":"LIMN","cik":1971387,"company_name":"Liminatus Pharma, Inc."},"pagination":{"limit":100,"returned":9,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"0ff5425b6f0b3715e56a2d29abfae4c967954775","cik":1971387,"ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-06-03T21:14:06+00:00","payload":{"action":"entry","agreement_name":"Inducement Letter Agreement","agreement_type":"equity_purchase","counterparty":"a holder of its existing common stock warrants","effective_date":"2026-06-03","item_codes_triggered":["1.01"],"value_text":"$1,861,920.00"},"claim":"Liminatus Pharma, Inc. entered into Inducement Letter Agreement with a holder of its existing common stock warrants valued at $1,861,920.00 (effective 2026-06-03).","evidence_excerpt":"On June 3, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter Agreement”) with a holder (the “Holder”) of its existing common stock warrants","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-070173","anchor_url":"https://secwatch.observer/filing/0001104659-26-070173#claim-0ff5425b6f0b3715e56a2d29abfae4c967954775","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/0001104659-26-070173-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"4bed6402d8e2d89d0da71ced1007f60871bb510b","cik":1971387,"ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-05-27T20:30:41+00:00","payload":{"company_response":"appeal_requested","compliance_status":"hearing_requested","cure_deadline":"2026-05-18","deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":"2026-05-26","immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-05-20","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(b)(2)(A)","5450(b)(2)(C)"],"rules_cited_in_text":true},"claim":"Liminatus Pharma, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).","evidence_excerpt":"May 20, 2026, the Company received a notice\nfrom Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will\nbe delisted from The Nasdaq Global Mark","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-066974","anchor_url":"https://secwatch.observer/filing/0001104659-26-066974#claim-4bed6402d8e2d89d0da71ced1007f60871bb510b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm"},{"fact_type":"governance_change","fact_key":"e382cf8a0ce58f16872be174347e88748a3bb273","cik":1971387,"ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-03-04T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-02-27","item_codes_triggered":["5.03"],"summary_text":"Reduced stockholder meeting quorum requirement from majority to one-third of voting power"},"claim":"Liminatus Pharma, Inc.: Reduced stockholder meeting quorum requirement from majority to one-third of voting power (effective 2026-02-27).","evidence_excerpt":"On February 27, 2026, the Board of Directors (the “Board”) of Liminatus Pharma, Inc. (the “Company”) approved an amendment to the Company’s bylaws (the “Bylaws”) to reduce the quorum requirement for meetings of the stockholders from a majority to one-third (1/3) of the voting power of the capital stock of the Company issued and outstanding and entitled to vote (the “Bylaw Amendment”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-023467","anchor_url":"https://secwatch.observer/filing/0001104659-26-023467#claim-e382cf8a0ce58f16872be174347e88748a3bb273","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926023467/0001104659-26-023467-index.htm"},{"fact_type":"material_agreement","fact_key":"9255b1ced023d08a9c69e213cbee8c7af389aed9","cik":1971387,"ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-02-18T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain purchasers party thereto","effective_date":"2026-02-17","item_codes_triggered":["1.01"],"value_text":null},"claim":"Liminatus Pharma, Inc. entered into Purchase Agreement with certain purchasers party thereto (effective 2026-02-17).","evidence_excerpt":"the Company entered into a securities purchase agreement (the \"Purchase Agreement\") with certain purchasers party thereto.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-017134","anchor_url":"https://secwatch.observer/filing/0001104659-26-017134#claim-9255b1ced023d08a9c69e213cbee8c7af389aed9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926017134/0001104659-26-017134-index.htm"},{"fact_type":"material_agreement","fact_key":"16f57b5f5c42d5db6623aeb5a1b630a599fe3d1c","cik":1971387,"ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-02-09T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Settlement Agreement","agreement_type":"settlement","counterparty":"Clear Street LLC","effective_date":"2026-02-06","item_codes_triggered":["1.01"],"value_text":null},"claim":"Liminatus Pharma, Inc. entered into Settlement Agreement with Clear Street LLC (effective 2026-02-06).","evidence_excerpt":"On February 6, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a settlement and release agreement (the “Settlement Agreement”) with Clear Street LLC (the “Holder”), pursuant to which the Company agreed to issue 4,000,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), to the Holder in exchange for the surrender and cancellation of 805,377 warrants (the “Warrants”) to purchase shares of Common Stock held by the Holder.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-012016","anchor_url":"https://secwatch.observer/filing/0001104659-26-012016#claim-16f57b5f5c42d5db6623aeb5a1b630a599fe3d1c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926012016/0001104659-26-012016-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"90adecce3d07424200f5bc0b1752e47dfc3b3add","cik":1971387,"ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-01-26T23:59:59+00:00","payload":{"company_response":"working diligently to regain compliance","compliance_status":"deficient","cure_deadline":"2026-07-14","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2026-01-15","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5450(a)(1)","reported_value":null,"rule_numbers":["5450(a)(1)"],"rules_cited_in_text":true},"claim":"Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"January 15, 2026, Liminatus Pharma, Inc.\n(the “Company”) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nindicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with\nNasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”) which requires listed securities to maintain a minimum bid\nprice of $1 per share. The notification has no immediate effect on the\nlisting of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-006619","anchor_url":"https://secwatch.observer/filing/0001104659-26-006619#claim-90adecce3d07424200f5bc0b1752e47dfc3b3add","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926006619/0001104659-26-006619-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"222d5aa2e2438499aa674f3305c64fca95b1c097","cik":1971387,"ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2025-11-25T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"May 18, 2026","deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"MVLS $50,000,000; MVPHS $15,000,000","notice_date":"2025-11-19","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5450(b)(2)(A), 5450(b)(2)(C)","reported_value":null,"rule_numbers":["5450(b)(2)(A)","5450(b)(2)(C)"],"rules_cited_in_text":true},"claim":"Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).","evidence_excerpt":"November 19, 2025, Liminatus Pharma, Inc. (the\n“Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that\nthe Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value\nof Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last\n30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly\nHeld Shares (MVPHS) of $15,000,000 (","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-116049","anchor_url":"https://secwatch.observer/filing/0001104659-25-116049#claim-222d5aa2e2438499aa674f3305c64fca95b1c097","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"a603603512b6d0882749bfdf2d41d69c1b8cbb02","cik":1971387,"ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2025-08-25T23:59:59+00:00","payload":{"company_response":"Company is in the process of completing the Form 10-Q and intends to file it as soon as practicable.","compliance_status":"deficient","cure_deadline":"2026-02-16","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-08-22","notice_type":"deficiency_notice","plan_due_date":"2025-10-21","raw_rule_text":"Nasdaq Listing Rule 5250(c)(1) due to delay in filing Quarterly Report on Form 10-Q","reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"August 22, 2025, Liminatus Pharma, Inc. (the\n“Company”) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that\nthe Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q\nfor the period ended June 30, 2025 (the “Form 10-Q”). The deficiency letter has no immediate effect\non the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “LIMN”\nat this time. Under the Nasdaq rules, the Company has 60 calendar\nda","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-082579","anchor_url":"https://secwatch.observer/filing/0001104659-25-082579#claim-a603603512b6d0882749bfdf2d41d69c1b8cbb02","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925082579/0001104659-25-082579-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"7f06ed450d64eb2544ec28c4755520610b054b4f","cik":1971387,"ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2025-06-04T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"regained_compliance","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-05-29","notice_type":"noncompliance_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"Liminatus Pharma, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"May 29, 2025, Liminatus Pharma, Inc. (the “Company”)\nreceived a notice from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC indicating\nthat the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) due to the delay in\nfiling its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Form 10-Q”). On June 2, 2025, the Company filed the Form 10-Q\nwith the U.S. Securities and Exchange Commission. On June 3, 2025, the Company received a letter\nfrom the Staff stating that the Company had regained compli","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-25-056421","anchor_url":"https://secwatch.observer/filing/0001104659-25-056421#claim-7f06ed450d64eb2544ec28c4755520610b054b4f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925056421/0001104659-25-056421-index.htm"}]}